Parthanatos has been indicated as a cell death modality in melanoma cells that acquired resistance to BRAFi and/or MEKi, and it was preferentially induced upon drug withdrawal in cell lines characterized with high levels of active ERK1/2 rebound in response to drug cessation [234]. The gene discussed is MAPK3; the disease is melanoma.